At Bogan Sleep Consultants, we are passionate about advancing medical research and improving patient care through innovative clinical trials. We invite you to explore our pulmonary clinical trials and see if you qualify to participate in these important studies.
Sanofi Asthma Study (LPS16676)
This study is a randomized, double-blind, placebo-controlled trial designed to assess the long-term effects of dupilumab on preventing lung function decline in patients with uncontrolled moderate to severe asthma. By participating, you can contribute to groundbreaking research and potentially benefit from cutting-edge treatment.
Eligibility Criteria:
InSilico (INS018-055-004)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects with Idiopathic Pulmonary Fibrosis (IPF).
Potential subjects will need to be diagnosed with Idiopathic Pulmonary Fibrosis. They must be able to complete a Spirometry and other testing at every visit. Subjects who are on the lung transplant list are not eligible for this trial. Subjects who are immunocompromised will not be eligible.
Why Participate in a Pulmonary Study?
By joining our clinical trials, you gain access to pioneering treatments and receive expert care from our dedicated team. Your involvement is crucial in contributing to medical advancements that could improve the lives of countless individuals with asthma and COPD.
If you meet the eligibility criteria and are interested in participating, we encourage you to contact us for more information. Our friendly team is here to support you every step of the way. Join us in making a difference in pulmonary health research and improving the future of lung care.
